{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:37:31Z","timestamp":1788820651679,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fusarium species represent an opportunistic fungal pathogen. The data in Mexico about Fusarium infections in humans are scarce. Here, we present a retrospective series of patients with a confirmed diagnosis of fusariosis in eight different hospitals in Mexico from January 2010 to December 2019. The diagnosis of proven fusariosis was made according to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORT\/MSG) criteria. A total of 49 cases were identified in our series. Most patients had burn injuries (49%), and 37% had hematological malignancies. Most patients had fire injuries (40%), followed by electric injuries (8%), febrile neutropenia (10%), and pancytopenia (6%). Patients had skin and soft tissue involvement in 49%, followed by blood culture isolation and biopsies from different sites of the body (lung, sinuses, bone tissue, and eyes). Febrile neutropenia (10%) and fungemia (8%) were the most common clinical syndromes in immunosuppressed patients. Most patients received monotherapy (67%), where voriconazole was used in 30% of the cases, followed by conventional amphotericin B (16%), and lipidic formulations of amphotericin B in 10% (either liposomal amphotericin B or amphotericin B lipid complex). Combination therapy was used in 20% of the cases, and the most common combination therapy was triazole plus any lipidic formulation of amphotericin B (10%). Mortality related to Fusarium infection occurred in 22% of patients. Fusariosis is a serious threat. Burn injuries and hematologic malignancies represent the most common causes of infection in this small series from Mexico.<\/jats:p>","DOI":"10.1093\/mmy\/myad112","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T20:01:06Z","timestamp":1699560066000},"source":"Crossref","is-referenced-by-count":10,"title":["Fusariosis in Mexico: A 10-year retrospective series"],"prefix":"10.1093","volume":"61","author":[{"given":"Armando","family":"Barrag\u00e1n-Reyes","sequence":"first","affiliation":[{"name":"Hospital M\u00e9dica Sur, Internal medicine department , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Esa\u00fa L\u00f3pez","family":"J\u00e1come","sequence":"additional","affiliation":[{"name":"Instiuto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra, Clinical microbiology laboratory. Infectious diseases division , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Perales-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital \u00c1ngeles San Luis, San Luis Potos\u00ed, M\u00e9xico \/ Hospital Regional de Alta Especialidad del Baj\u00edo, Leon. Infectious diseases and hospital epidemiology division , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Nava-Ruiz","sequence":"additional","affiliation":[{"name":"Hospital de Especialidades Pedi\u00e1ricas, Pediatric infectious diseases, Tuxtla Guti\u00e9rrez , Chiapas , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda de Lourdes Garc\u00eda","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Instiuto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra, Clinical microbiology laboratory. Infectious diseases division , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cornejo-Ju\u00e1rez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancerolog\u00eda, Infectious diseases division , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Rinc\u00f3n-Zuno","sequence":"additional","affiliation":[{"name":"Instituto materno Infantil del Estado de M\u00e9xico, Infectious diseases department , Toluca , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Camacho","sequence":"additional","affiliation":[{"name":"Hospital Universitario Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez, Hospital epidemiology and infectious diseases division , Monterrey , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-1138","authenticated-orcid":false,"given":"Rafael Franco","family":"Cendejas","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Rehabilitaci\u00f3n Luis Guillermo Ibarra Ibarra , Clinical microbiology laboratory. Infectious diseases division. Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M Feliciano","family":"Guzm\u00e1n","sequence":"additional","affiliation":[{"name":"Hospital de Especialidades Pedi\u00e1ricas, Pediatric infectious diseases, Tuxtla Guti\u00e9rrez , Chiapas , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-1234","authenticated-orcid":false,"given":"Norma E","family":"Rivera-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital regional de alta especialidad de Oaxaca, Infectious diseases division , Oaxaca , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Onta\u00f1\u00f3n-Zurita","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancerolog\u00eda, Infectious diseases division , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Res\u00e9ndiz-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Hospital Infantil de M\u00e9xico Federico G\u00f3mez , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ju\u00e1rez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital M\u00e9dica Sur, Infectious diseases. Translational Research Unit , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-1301","authenticated-orcid":false,"given":"Daniel","family":"Aguilar-Zapata","sequence":"additional","affiliation":[{"name":"Hospital M\u00e9dica Sur, Infectious diseases. Translational Research Unit , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"2023120112202695300_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/CMR.7.4.479","article-title":"Taxonomy, biology, and clinical aspects of Fusarium species","volume":"7","author":"Nelson","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"2023120112202695300_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1055\/s-0035-1562897","article-title":"Fusariosis","volume":"36","author":"Nucci","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2023120112202695300_bib3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/342328","article-title":"Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management","volume":"35","author":"Nucci","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2023120112202695300_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4612-2762-5_9","article-title":"Fusarium-caused hyalohyphomycosis: an overview","volume":"4","author":"Anaissie","year":"1992","journal-title":"Curr Top Med Mycol"},{"key":"2023120112202695300_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2018.04.3542","article-title":"Epidemiology of Fusarium, a significant emerging group of human opportunistic infections","volume":"73","author":"Nucci","year":"2018","journal-title":"Int J Infect Dis"},{"key":"2023120112202695300_bib6","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023120112202695300_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-6640-7_16","article-title":"Hyalohyphomycoses (Hyaline Moulds)","volume-title":"Essentials of Clinical Mycology","author":"Torres","year":"2011","edition":"2nd edn."},{"key":"2023120112202695300_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1099\/00222615-48-4-363","article-title":"Experimental pathogenicity of four opportunist Fusarium species in a murine model","volume":"48","author":"Mayayo","year":"1999","journal-title":"J Med Microbiol"},{"key":"2023120112202695300_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/CMR.19.2.403-434.2006","article-title":"Burn wound infections","volume":"19","author":"Church","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"2023120112202695300_bib10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.burns.2008.04.007","article-title":"Incidence of systemic fungal infection and related mortality following severe burns","volume":"34","author":"Murray","year":"2008","journal-title":"Burns"},{"key":"2023120112202695300_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"key":"2023120112202695300_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023120112202695300_bib13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3201\/eid1910.120847","article-title":"Increased incidence of invasive fusariosis with cutaneous portal of entry","volume":"19","author":"Nucci","year":"2013","journal-title":"Brazil Emerg Infect Dis."},{"key":"2023120112202695300_bib14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.29312\/remexca.v9i8.756","article-title":"Molecular identification of Fusarium spp. isolated maize in Sinaloa, Mexico","volume":"9","author":"Velarde\u00a0F\u00e9lix","year":"2018","journal-title":"Revista mexicana de ciencias agr\u00edcolas"},{"key":"2023120112202695300_bib15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/ICO.0b013e31819bc2ea","article-title":"Fusarium keratitis in Mexico","volume":"28","author":"P\u00e9rez-Balbuena","year":"2009","journal-title":"Cornea"},{"key":"2023120112202695300_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.burns.2014.10.024","article-title":"Epidemiology of filamentous fungal infections in burned patients: a French retrospective study","volume":"41","author":"Schaal","year":"2015","journal-title":"Burns"},{"key":"2023120112202695300_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bjid.2016.04.004","article-title":"Fusarium spp. infections in a pediatric burn unit: nine years of experience","volume":"20","author":"Rosanova","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"2023120112202695300_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998\u20132009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"key":"2023120112202695300_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13756-017-0247-3","article-title":"Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia","volume":"6","author":"Carlesse","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023120112202695300_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.idc.2006.06.002","article-title":"Emerging fungi","volume":"20","author":"Nucci","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"2023120112202695300_bib21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V90.3.999","article-title":"Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years\u2019 experience at a cancer center and implications for management","volume":"90","author":"Boutati","year":"1997","journal-title":"Blood"},{"key":"2023120112202695300_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2023120112202695300_bib23","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"French Mycoses Study Group. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023120112202695300_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.46.1.245-247.2002","article-title":"In vitro\u00a0synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp","volume":"46","author":"Arikan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2023120112202695300_bib25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1345\/aph.1D292","article-title":"Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia","volume":"39","author":"Makowsky","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2023120112202695300_bib26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/01.inf.0000143649.90952.41","article-title":"Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole","volume":"23","author":"Guzman-Cottrill","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2023120112202695300_bib27","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/JCM.41.10.4898-4900.2003","article-title":"Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia","volume":"41","author":"Durand-Joly","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2023120112202695300_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00277-003-0795-x","article-title":"Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B","volume":"83","author":"Rothe","year":"2004","journal-title":"Ann Hematol"},{"key":"2023120112202695300_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-002-0877-z","article-title":"Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine","volume":"22","author":"Howden","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023120112202695300_bib30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy","volume":"52","author":"Jenks","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023120112202695300_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MD.0000000000000008","article-title":"Fusarium infection: report of 26 cases and review of 97 cases from the literature","volume":"92","author":"Muhammed","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"2023120112202695300_bib32","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2023120112202695300_bib33","doi-asserted-by":"crossref","first-page":"ofv099","DOI":"10.1093\/ofid\/ofv099","article-title":"Invasive fusariosis in the voriconazole era: single-center 13-year experience","volume":"2","author":"Stempel","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2023120112202695300_bib34","first-page":"1165","article-title":"Update on the treatment of disseminated fusariosis: focus on voriconazole","volume":"3","author":"Stanzani","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2023120112202695300_bib35","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1086\/429331","article-title":"Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex","volume":"40","author":"Perfect","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023120112202695300_bib36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1046\/j.1365-2141.2000.01856.x","article-title":"The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years","volume":"108","author":"Musa","year":"2000","journal-title":"Br J Haematol"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad112\/52997451\/myad112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/12\/myad112\/53966922\/myad112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/12\/myad112\/53966922\/myad112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:21:04Z","timestamp":1701433264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad112\/7379596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad112","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,11,7]]},"article-number":"myad112"}}